Compare Aurobindo Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs BIOCON - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA BIOCON AUROBINDO PHARMA/
BIOCON
 
P/E (TTM) x 18.7 30.5 61.2% View Chart
P/BV x 3.8 3.9 97.2% View Chart
Dividend Yield % 0.3 0.3 110.1%  

Financials

 AUROBINDO PHARMA   BIOCON
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
BIOCON
Mar-19
AUROBINDO PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs830707 117.3%   
Low Rs527554 95.2%   
Sales per share (Unadj.) Rs333.991.9 363.3%  
Earnings per share (Unadj.) Rs40.416.7 241.5%  
Cash flow per share (Unadj.) Rs51.824.2 214.1%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.40.2 232.3%  
Book value per share (Unadj.) Rs237.1101.6 233.3%  
Shares outstanding (eoy) m585.91600.00 97.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.06.9 29.6%   
Avg P/E ratio x16.837.7 44.6%  
P/CF ratio (eoy) x13.126.1 50.3%  
Price / Book Value ratio x2.96.2 46.1%  
Dividend payout %6.26.0 103.5%   
Avg Mkt Cap Rs m397,569378,330 105.1%   
No. of employees `00017.96.1 291.2%   
Total wages/salary Rs m25,84911,653 221.8%   
Avg. sales/employee Rs Th10,956.98,994.3 121.8%   
Avg. wages/employee Rs Th1,447.71,900.7 76.2%   
Avg. net profit/employee Rs Th1,324.31,635.3 81.0%   
INCOME DATA
Net Sales Rs m195,63655,144 354.8%  
Other income Rs m1,5531,444 107.6%   
Total revenues Rs m197,18956,588 348.5%   
Gross profit Rs m39,51915,883 248.8%  
Depreciation Rs m6,6804,478 149.2%   
Interest Rs m2,626709 370.4%   
Profit before tax Rs m31,76712,140 261.7%   
Minority Interest Rs m279 300.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,123 342.4%   
Profit after tax Rs m23,64510,026 235.8%  
Gross profit margin %20.228.8 70.1%  
Effective tax rate %22.917.5 130.8%   
Net profit margin %12.118.2 66.5%  
BALANCE SHEET DATA
Current assets Rs m153,64548,228 318.6%   
Current liabilities Rs m120,42930,376 396.5%   
Net working cap to sales %17.032.4 52.4%  
Current ratio x1.31.6 80.4%  
Inventory Days Days13568 198.0%  
Debtors Days Days6486 74.5%  
Net fixed assets Rs m103,90964,130 162.0%   
Share capital Rs m5863,000 19.5%   
"Free" reserves Rs m138,32257,980 238.6%   
Net worth Rs m138,90860,980 227.8%   
Long term debt Rs m1,80015,766 11.4%   
Total assets Rs m264,544121,924 217.0%  
Interest coverage x13.118.1 72.3%   
Debt to equity ratio x00.3 5.0%  
Sales to assets ratio x0.70.5 163.5%   
Return on assets %9.98.8 112.8%  
Return on equity %17.016.4 103.5%  
Return on capital %23.816.8 142.3%  
Exports to sales %49.628.1 176.5%   
Imports to sales %18.818.9 99.6%   
Exports (fob) Rs m97,09115,506 626.2%   
Imports (cif) Rs m36,74110,399 353.3%   
Fx inflow Rs m97,31615,506 627.6%   
Fx outflow Rs m40,58910,399 390.3%   
Net fx Rs m56,7275,107 1,110.8%   
CASH FLOW
From Operations Rs m16,22011,546 140.5%  
From Investments Rs m-28,768-7,138 403.0%  
From Financial Activity Rs m19,191-2,417 -794.0%  
Net Cashflow Rs m6,6562,103 316.5%  

Share Holding

Indian Promoters % 54.1 40.4 133.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.0 8.4 94.6%  
FIIs % 27.7 10.7 258.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 19.9 51.3%  
Shareholders   69,601 109,995 63.3%  
Pledged promoter(s) holding % 8.6 0.0 21,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS